Member Info for Moneymunch

Share accumulation in progress, any shares sold cheaply are beeing hoovered UP!!! Gla holders, multiple potential material newsflow in the pipeline, including a tranche of the outstanding non-dilutive grant money, which will add significant UPside!!! On and UP!!! :-)

They'll be paying 2p plus regardless of any RNS, and more like 3p plus and more on the next UPdate....Genflow is all set for a Major re-rate or two. Gl :')

Lol, dream on, Genflow is in full focus and has turned a huge corners as they fast approach the business end of their R & D....the massive buying volumes witnessed shouldn't have given you a clue. Gla holders,a Major move North beckons!!! :-)

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

2,127 followers

20h

By studying #SIRT6's effects on dog #aging, we'll better understand its application towards humans!

The dog anti-aging market is estimated to be $520 million. The human anti-aging market? $75 billion.

#GENF #GENFF

.......

Genflow hits safety milestone in ageing therapy for dogs: Genflow Biosciences (LON:GENF) (OTCQB:GENFF) , the London-listed longevity company, has reached a key milestone in its effort to see whether a human gene linked to long life can slow ageing in dogs.

The company said its experimental SIRT6 gene therapy, based on a version found in people who live beyond 100, had been safely given for the second time to a group of elderly beagles with no signs of side effects.

The study involves 28 dogs aged ten and above and is due to finish in January 2026.

The trial is designed to test whether the SIRT6 gene can help cells repair DNA and regulate metabolism, both of which tend to deteriorate with age.

The dogs are divided into two groups, with some receiving different versions of the therapy while others remain untreated. Genflow said that after the second round of treatment, the therapy continued to show an excellent safety profile.

The SIRT6 gene, sourced from human centenarians, is believed to play an important role in... hxxp://dlvr.it/TNb9Y2

.......

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

2,127 followers

3d

Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is conducting the world's first longevity gene therapy trial for #dogs!

Over the next couple months, we'll be answering the most common questions we've been asked about GF-1004.

Follow us to stay up-to-date!

#GENF #GENFF #Aging #GeneTherapy

Lovely indeed Porter, all bodes well for a Major re-rate or two. Gl :-)

Despite the best efforts of someone intent on trashing the thread, presumably to discourage pi's from buying, the chart now looks perfectly poised and primed for the next move North in anticipation of incoming news. Gla holders, hold on tight and enjoy the ride, Genflow's prospects and potential, both near and mid term could be transformational for all invested as Eric continues to deliver!!! :-)

Potential Game Changing news at anytime!!! Gla holders:-)

I'd buy the 1m at that price then, this is going to go BIG, very soon!!! Gla holders....Game changing news fast approaching!!! :-)

Nice one Northeast, my expectations too given the turnaround in fortunes and staggering buying volumes/pressure we've witnessed, although I remember you mentioned who you know, and so hopefully and presumably, he knows more than most!!! Exciting times ahead and potential game changing news fast approaching....in Eric we Trust!!! :'))

Human Health Pipeline

In human health, our pipeline spans MASH ("Metabolic Dysfunction-Associated Steatohepatitis"), sarcopenia, Werner Syndrome, and exploratory programs in ophthalmology. Collectively, these programs highlight the versatility of SIRT6 centenarian in addressing fundamental mechanisms of aging across multiple systems.

The most notable development has been in MASH. Recent approvals of two new therapies including GLP-1 agonists have provided effective therapies for patients in the earlier stages of disease (approximately two-thirds of the population). However, there remains a profound unmet need in advanced MASH with fibrosis, where therapeutic options are extremely limited. In response, Genflow has repositioned GF-1002 to target this high-need population (around one-third of patients). With its antifibrotic properties and potential to prevent progression to liver cancer, GF-1002 is uniquely suited to address this stage of disease. While the patient population is smaller, the commercial opportunity is significant, given the lack of alternatives beyond liver transplantation.

In parallel, we are expanding into ophthalmology, where SIRT6-based therapies hold promise in corneal pathologies and glaucoma. Current glaucoma treatments focus primarily on reducing intraocular pressure, yet do not prevent degeneration of the optic nerve. Preclinical findings suggest that SIRT6 overexpression can protect retinal ganglion cells and preserve optic nerve integrity, opening the door to a paradigm shift in treatment - from symptom management to true neuroprotection. With the global glaucoma market valued at nearly USD 9 billion and projected to reach USD 12-14 billion by the early 2030s, this represents a compelling long-term growth opportunity for Genflow.

2025 pharma M&A surges to $70 billion in major deals

October 10, 2025

After a cautious Q2 amid FDA workforce changes and drug pricing policy debates, deal flow accelerated dramatically in Q3-Q4. September alone saw $8.7B in activity, with the MASH land grab (Roche, Novo) and Pfizer’s obesity re-entry ranking among the largest deals.

.....

The MASH land grab: Novo’s $5.2B bet in context

The escalating competition for MASH assets is evident in rapidly increasing deal values. Within 150 days, three pharmaceutical giants committed $8.3 billion upfront to acquire FGF21 analogs. Novo Nordisk’s $4.7 billion payment for Akero nearly doubles the $2.4 billion Roche paid for 89bio just three weeks earlier and quadruples GSK’s $1.2 billion for Boston Pharmaceuticals’ efimosfermin-alfa in May.

2025 pharma M&A surges to $70 billion hTtps://share.google/P4UdTbyqA3BYyx50q

Brilliant interview with Eric and Proactive on yesterday's news. Gla :-)

10/10/25

Take a look at this video, 'genflow biosciences' htTps://share.google/15CPbuD76CpAjyOBP

Perfectly poised for more upward momentum next week imho, wouldn't be surprised to see 3p tested and much more on news of non-dilutive grant funding etc....Gla holders, hold tight and enjoy the ride, and good luck to all those who took their profits, but it might be difficult to get back in at whatever price you sold if grant funding or other material news drops on Monday.....On and UP!!! :-)

Tree shake....hold on tight and enjoy the ride....Genflow are on a one way trajectory from small cap to mid cap!!! Gla ;-)

Looking forward to the receipt confirmation of a tranche of the outstanding €4.7m non-dilutive grant funding money from the Wallonia Govt in Belgium, which is awaiting "initial disbursement is pending the completion of standard administrative procedures on the government's side".....confirmation of more non-dilutive cash in the bank will be very well received and could be imminent imho.....multiple newsflow from the rest of the pipeline at anytime. Gla Holders....Genflow are on track from small cap to mid cap in the coming weeks and months and offers the rare opportunity for exponential returns for those invested as this bargain low. :-)

Genflow is all set for Stardom!!! Gla holders ;-)

Another significant opportunity for a lucrative JV licensing deal........News on the Material Transfer Agreement (MTA) with a leading ophthalmology company, could land at anytime. Gla Holders:-)

10/4/25

Ophthalmology: Genflow launched a new development program in ophthalmology, focused on advancing a novel gene therapy leveraging its proprietary centenarian SIRT6 (centSIRT6). This therapy will utilize a specially designed non-viral vector engineered for precise delivery of Genflow's centSIRT6 to different compartments of the eye. The therapy is designed to combat ocular problems including several pathologies of the cornea and glaucoma. This initiative is part of Genflow's continued efforts to optimize its gene therapy and proprietary centenarian SIRT6.

As part of this effort, Genflow has signed a Material Transfer Agreement (MTA) with a leading ophthalmology company, to collaborate on the design and development of the eye-targeted centSIRT6 non-viral vector to target ocular diseases. These therapies will leverage Genflow's proprietary centSIRT6 Centenarian gene technology, in combination with an advanced vector delivery system.

"We're very encouraged by the continued safety validation of our SIRT6 therapy and by the strong engagement we're seeing from established players in the animal health industry. "

10 October 2025

Genflow Biosciences Plc

Update on Animal Health Program

LONDON, UK-Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is pleased to provide an update on its Dog Aging (GF-1004) study, a proof-of-concept clinical trial evaluating the safety and efficacy of its proprietary SIRT6-centenarian gene therapy for age-related decline in elderly dogs.

Genflow's proprietary centenarian SIRT6 gene therapy has now been administered for the second time in its ongoing randomized, controlled trial involving 28 beagles aged 10 years and older. In March, recipients received three different modalities of SIRT6 gene therapy with no ill or adverse effects observed, while control animals remained untreated. The repeat administration has again demonstrated an excellent safety and tolerability profile, marking a key milestone in the study. The dogs are in a follow-up period expected to conclude in January 2026.

This successful second administration underscores the robustness of Genflow's gene therapy platform and its potential applicability beyond human health. The SIRT6 gene, sourced from human centenarians, plays a vital role in DNA repair, metabolic regulation, and resistance to age-related decline. By leveraging this unique gene variant, Genflow aims to introduce a new class of longevity-based treatments into the multi-billion-dollar global animal health market, targeting improved healthspan, vitality, and lifespan in companion and livestock animals.

Dr. Eric Leire, Chief Executive Officer of Genflow Biosciences, commented: "We're very encouraged by the continued safety validation of our SIRT6 therapy and by the strong engagement we're seeing from established players in the animal health industry. The animal health market represents an attractive near-term commercial opportunity for Genflow, complementing our core human longevity programs while showcasing the broader potential of our gene therapy platform."

With safety confirmed in repeat administration, Genflow will continue to advance its animal health initiative toward the next stage of clinical evaluation and partnership development. The Company remains committed to creating value for shareholders through innovation, collaboration, and leadership in the emerging field of genetic longevity therapeutics.

How much for Genflow’s MASH prospect with their cutting-edge science and panacea potential of their Centenarian SIRT6 Gene Therapy??? Gla holders...and amazing and very exciting period ahead for all invested. ;-)

9/10/25

Novo inks Akero buyout worth up to $5.2B to bag late-phase MASH prospect

....

Novo will face competition for the opportunity. Madrigal Pharmaceuticals’ Rezdiffra is already approved in MASH, and a clutch of companies is giving chase. Roche is set to join the race through its deal to buy 89bio for up to $3.5 billion.

Novo inks $4.7B Akero buyout to bag late-phase MASH prospect htTps://share.google/HmQKehk7Q8kkIts0k